You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Medtronic
Baxter
Boehringer Ingelheim
AstraZeneca

Last Updated: April 14, 2021

DrugPatentWatch Database Preview

NURTEC ODT Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Nurtec Odt, and what generic alternatives are available?

Nurtec Odt is a drug marketed by Biohaven Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-three patent family members in thirty-three countries.

The generic ingredient in NURTEC ODT is rimegepant sulfate. Additional details are available on the rimegepant sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Nurtec Odt

Nurtec Odt will be eligible for patent challenges on February 27, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for NURTEC ODT
International Patents:83
US Patents:2
Applicants:1
NDAs:1
Bulk Api Vendors: 27
Clinical Trials: 1
Patent Applications: 28
Drug Prices: Drug price information for NURTEC ODT
What excipients (inactive ingredients) are in NURTEC ODT?NURTEC ODT excipients list
DailyMed Link:NURTEC ODT at DailyMed
Drug patent expirations by year for NURTEC ODT
Drug Prices for NURTEC ODT

See drug prices for NURTEC ODT

DrugPatentWatch® Estimated Generic Entry Opportunity Date for NURTEC ODT
Generic Entry Date for NURTEC ODT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, ORALLY DISINTEGRATING;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NURTEC ODT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Weill Medical College of Cornell UniversityPhase 2
Biohaven Pharmaceuticals, Inc.Phase 2

See all NURTEC ODT clinical trials

US Patents and Regulatory Information for NURTEC ODT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biohaven Pharm NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Biohaven Pharm NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Biohaven Pharm NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Harvard Business School
McKesson
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.